|
PSMB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
2.642100E-04 |
| Normal-vs-Stage3 |
4.55191440096314E-15 |
| Normal-vs-Stage4 |
6.68009980664408E-10 |
| Stage1-vs-Stage2 |
2.975200E-01 |
| Stage1-vs-Stage3 |
2.968000E-01 |
| Stage1-vs-Stage4 |
5.536200E-01 |
| Stage2-vs-Stage3 |
1.224000E-01 |
| Stage2-vs-Stage4 |
1.990160E-01 |
| Stage3-vs-Stage4 |
8.540400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.65980000024868E-07 |
| Normal-vs-Asian |
2.85800000332515E-08 |
| Caucasian-vs-AfricanAmerican |
2.669400E-01 |
| Caucasian-vs-Asian |
4.174600E-01 |
| AfricanAmerican-vs-Asian |
1.249600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.03603800486007E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.814200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
1.55431223447522E-15 |
| Normal-vs-Age(61-80Yrs) |
3.04839997689044E-09 |
| Normal-vs-Age(81-100Yrs) |
1.55688999999848E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.609200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.347020E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.825600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.219000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.718000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.016200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.400500E-02 |
| Classical-VS-Follicular |
1.217030E-03 |
| Classical-VS-Other |
3.361600E-02 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
2.47029999999038E-05 |
| Tall-VS-Other |
9.377000E-04 |
| Tall-VS-Normal |
1.6251444634463E-12 |
| Follicular-VS-Other |
7.786400E-01 |
| Follicular-VS-Normal |
2.158600E-03 |
| Other-VS-Normal |
1.274010E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.56301663120939E-14 |
| Normal-vs-N1 |
6.50609999985896E-07 |
| N0-vs-N1 |
5.046200E-01 |
|
|
